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ABSTRACT 
The main objective of the present study is too prepared, characterized and evaluate and surfactant used as a carrier in solid 
dispersions for enhancing the dissolution rate of simvastatin. The feasibility of formulating solid dispersions of pure drug with gum 
and surfactant combination that enhanced dissolution rate was also investigated. Solid dispersions of simvastatin in gum: surfactant 
different polymer ratios were prepared by kneading method and evaluated for dissolution rate and efficiency. All the solid 
dispersions prepared gave rapid and higher dissolution of simvastatin when compared with pure drug. The DE60 was also increased 
from many folds in the case of pure drug and solid dispersions. Experimental design was applied systematically and determine the 
influence of the individual and combined effect on independent variables (X1) ratio and (X2) concentration of surfactants on the 
dependent variables percent dissolution efficiency at 60 min (%DE 60) and yield percent and optimized formulation selected and 
characterised by its UV, Differential scanning caloriemetery, Scanning electron microscopy and X- Diffraction studies and 
formulated into capsule dosage form. In conclusion, the result of this work to suggest that solid dispersion is a useful technique for 
enhancing the solubility and dissolution study of water insoluble drug. 
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INTRODUCTION 
Today most challenging and important aspects in the 
pharma industries are related with strategies that 
improved and enhanced the solubility of poorly soluble 
drugs. Low solubility and dissolution rate of water 
insoluble drugs in the aqueous gastrointestinal fluids and 
cause insufficient bioavailability and especially for 
Class II category according to the Biopharmaceutics 
Classification System (BCS), the bioavailability may be 
enhanced by increasing the solubility and dissolution 
rate of the drug in the gastro-intestinal fluids.
1
  The 
production of solid dispersions (SDs) is one of the 
acknowledged methods and used to enhance the aqueous 
solubility, thereby increasing the oral bioavailability and 
dissolution rate of drugs with aqueous low solubility
2, 3
. 
Greater stability, easy production, accurate dosage form 
and patient‘s perspective are the main reasons behind 
the preference of solid oral dosage form. Solid 
dispersions are one of the most successful strategies to 
improve the drug release profile of the water insoluble 
drugs
4, 5
. Simvastatin is a 2,2-Dimethylbutanoic acid 
(1S,3R,7S,8S,8aR)-1,2,3,7,8,8ahexahydro–3,7–
dimethyl–8-[2-[(2R,4R)-tetrahydro–4 hydroxy–6–oxo–
2Hpyran–2yl]ethyl]-1–naphthalenyl ester (BCS Class II) 
and  cholesterol lowering agent and synthetically 
obtained from Aspergills terreus. It is a potent inhibitor 
of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-Co 
A) Reductase which catalyzes the conversion of HMG-
Co A to mevalonate and inactive lactone is rapidly 
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metabolized to its corresponding beta-hydroxy acid 
(Simvastatin acid, SVA) after oral administration
 6, 7
. 
Locust Bean Gum (LBG) (Carob Gum) is mainly 
consisting of the high molecular weight 
(approximately50,000-3,000,000)polysaccharides 
composed of galactomannans and obtained from the 
refined endosperm of seeds from the carobtree 
Ceretonia Siliqua and evergreen tree of the legume 
family and a white to yellowish white, nearly odourless 
powder and insoluble in most organic solvents.
8, 9
 The 
Poloxamer polyols as a series of closely related block 
copolymers of ethylene oxide and propylene oxide 
conforming to the general formula O 
(C2H4O)a(C3H6O)b(C2H4O)H and group of block 
copolymer non-ionic surfactants and widely used as 
emulsifiers, solubilising agents, and suspension 
stabilizers in liquid, oral, topical, and parenteral dosage 
forms, wetting agents and plasticizers, and give better 
results for enhancing the solubility and dissolution of 
sparingly soluble drugs in solid dosage Poloxamer 188 
(POL) is a non-ionic block copolymer chain and widely 
used for  increasing the aqueous solubility of poorly 
water-soluble drugs and thus selected as a carrier for 
dissolution enhancement of a poorly water-soluble 
drug.
10, 11
 
MATERIAL AND METHODS 
Material 
The pure drug gift sample simvastatin received from Dr. 
Reddys’ Pharmaceuticals’ Ltd. Hyderabad. The 
hydrophilic surfactant Poloxamer 188 received as a gift 
sample from Sigma Aldrich Chem P Ltd. Mumbai and 
other chemicals i.e. ethanol, methanol, magnesium state, 
talc, lactose, disodium hydrogen orthophosphate and 
potassium dihydrogen orthophosphate were purchased 
from Loba Chemicals Mumbai, India. 
Methods 
Characterisation Parameters of pure drug 
The pure drug sample was analysed by different means 
such as colour, odour and texture in order to prove the 
authenticity of the sample.  
Solubility Determination of pure drug sample by UV 
spectroscopy 
Absorption maxima of pure drug (λ max) 
The pure drug sample was determined in different 
solvents by preparing the 10µg/ml solution of the drug 
and its absorption maxima was scanned by UV 
spectrophotometer between 200nm-400nm. 
Preparation of Standard Plot in Distilled water 
Pure drug sample (50mg) was dissolved in small amount 
of methanol (used as cosolvent), and diluted to 100ml of 
distilled water. 50ml of this solution was taken and 
diluted to 100ml with distilled water to prepare a stock 
solution of 250µg/ml as a stock solution and prepared 
aliquots of 0.1ml, 0.2ml, 0.3ml, 0.4ml, 0.5ml, 0.6ml and 
0.7ml and transferred to 10ml volumetric flask and 
volume was made up to 10ml with distilled water. The 
absorbance of these solutions was measured at 239nm 
using distilled water as blank. 
Characterisation parameters of LBG/MLBG
 12
 
Viscosity measurement 
 The viscous nature of locust bean gum and modified 
locust bean gum was measured at 37±1
o
C by using 
searle type viscometer, DV-E- Brookfield Viscometer, 
with spindle number 62 at 10 rpm. 
Angle of repose 
The accurately weighed powder was taken in a funnel 
and height of a funnel was adjusted in such a way and 
its tip just touches the apex of the heap of powder and 
allowed to ﬂow through funnel freely onto the surface. 
The diameter of the powder heap was measured and 
angle of repose was calculated by using the following 
equation: 
tan (θ) = h/r                                               Eq. 1 
h Height of powder heap  and r Radius of powder heap 
Density 
The loose bulk density (LBD) and tapped bulk density 
(TBD) of LBG/MLBG powder were determined. 
Powdered gum (2 gm) was poured into calibrated 
measuring cylinder (10 ml capacity) and noted initial 
volume and cylinder was allowed to fall under its own 
weight onto the hard surface from the height of 2.5 cm. 
The tapping was then continued until no further change 
in volume was noted. LBD and TBD were calculated 
using the following equation: 
LBD = Wt of the powder/Volume of the packing               Eq 2 
TBD = Wt of the powder/Tapped volume of the packing   Eq 3 
Phase Solubility Studies 
Solubility measurements were performed in which 
excess amount of pure drug (20mg) was added in 20ml 
of distilled water containing increasing concentrations 
of the MLBG (i.e. 0.25%, 0.5%, 1%, 1.25%, 1.5%, and 
2%) in screw capped vials, sealed and shaken at room 
temperature for 48h on a water bath shaker and the 
samples were filtered and analysed spectrophometrically 
at 239nm. 
Kneading method 
Accurately weighed pure drug and MLBG in drug: 
polymer ratio of 1:2, 1:5, and 1:8 for 5 min using glass 
mortar and pestle and physical mixture was triturated by 
using a small volume of ethanol-water solution and form 
a thick paste and kneaded for 30 min respectively, dried 
at 45
o
C in an oven. The dried mass was pulverized and 
passed through 60 mesh sieve size, weighed and 
transferred to airtight container and stored for further 
use 
13, 14
.  
Characterisation of Solid dispersions  
Determination of percentage yield and drug content
15
 
Drug content   
Pure drug and solid dispersions equivalent to 10 mg 
dissolved in  a suitable amount of methanol (25ml), 
filtered,  suitably diluted with methanol and  drug 
content was  analyzed by  UV spectrophotometer.  
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Percentage yield  
The percentage yield of the solid dispersions and the 
total weight of drug and carrier used and calculated by 
following equation: 
 % Yield= (a/b+ c)*100                            Eq. 4  
Whereas, a: the weight of the solid dispersion sifted and 
b: the weight of simvastatin taken for solid dispersion 
preparation c: the weight of the MLBG and the 
wei4wght of surfactant.   
Determination of solubility of solid dispersions 
Simvastatin and different solid dispersions equivalent to 
10 mg were weighed and added in 10 ml of Phosphate 
buffer pH 6.8 in screw capped vials and capped tightly, 
vortexed for 2 min and shaken at 37±2
o
C in a 
temperature controlled water bath for 24 hrs.  Resultant 
samples containing un-dissolved solid dispersions 
suspended in the screw capped vials were centrifuged 
and filtered, suitably diluted with phosphate buffer pH 
6.8 and analyzed by UV spectrophotometer at 239.5 nm.   
 In-vitro drug release studies
 15
 
Dissolution studies were conducted by using USP XXIV 
paddle method (apparatus 2) official in USP and Pure 
drug and solid dispersions equivalent to 10mg of 
simvastatin was added in 900ml phosphate buffer pH6.8 
at speed of 100 rpm at temperature of 37±0.5
o
C and 
pipette out 10ml solution was collected periodically and 
replaced with 10ml of freshly prepared dissolution 
medium and collected samples were analysed at 
239.5nm by using UV-visible spectrophotometer against 
phosphate buffer pH6.8 used as blank.  
Experimental Design  
The various type of designs available for the 
optimization of dosage form and full factorial design 
was selected with its systematically study that effect 
upon the influence of the individual and combined effect 
of independent variables  ratio  (X1)  and  concentration 
of surfactants (X2) on the dependent  variables percent 
dissolution efficiency at 60 min (%DE 60) and  percent 
yield. In this design, two factors are evaluated each at 
three levels and experimental trials were performed at 
all nine possible combinations and statistical model 
incorporating interactive and polynomial terms is used 
to evaluate the response
16
. 
Y= b0 + b1X1 + b2 X2+ b12 X1X2 + b11(X1)
2+ b22(X2)
2         Eq. 
5                        
Where, Y is the dependent variable, b0 is the arithmetic 
mean response of the nine runs, and b1 is the estimated 
coefficient for the factor X1 and main effects (X1 and 
X2) represent the average result of changing one factor 
at a time from its low to high value and interaction terms 
(X1 X2) show the responsive changes when two factors 
are simultaneously changed. The polynomial terms 
((X1)
2
and (X2)
2
) were included to investigate 
nonlinearity.
 
Table 1: Composition of factorial batches using Poloxamer 188 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characterization of Optimized Solid Dispersions  
Differential scanning calorimetry  
Thermal analyses were performed on the sample of pure 
drug and optimized solid dispersions were placed in a 
sealed aluminium pan and heated at a scanning rate of 
30
o
C/min from 25
o
C to 200
o
C temperature range.   
Fourier transform infrared spectroscopy 
Fourier transform infrared (FT-IR) spectroscopy was 
employed to characterize the possible interactions 
between the drug and the carrier in the solid state on an 
FT-IR spectrophotometer by the conventional KBr pellet 
method.  
 Powder x-ray diffraction analysis (XRD)  
Powder XRD patterns of pure drug and optimized solid 
dispersion were recorded using diffractometer Philips 
Variables levels in coded 
Batch 
 code 
X1  
(Ratio) 
X2  
(Concentration) 
SIM 22 -1 -1 
SIM 25 -1 0 
SIM 28 -1 +1 
SIM 23 0 -1 
SIM 26 0 0 
SIM 29 0 +1 
SIM 24 +1 -1 
`SIM 27 +1 0 
SIM 30 +1 +1 
Coded values Actual values Concentration of surfactant 
Poloxamer 188 ( % w/w) 
-1 1:2 4 
0 1:5 8 
+1 1:8 12 
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PW 1729 X-ray generator under the following 
conditions: target CuKa monochromatized radiations, 
voltage 40 KV, and current 40 mA at ambient 
temperature.  
Scanning electron microscopy (SEM)  
The scanning electron microscopy (SEM) analysis was 
carried out on the samples of pure drug and the 
optimized solid dispersions were mounted onto the stubs 
using double-sided adhesive tape and then coated with a 
thin layer of gold palladium alloy (150–200A°).  
Formulation of Optimized Batch into Capsules 
Dosage Form  
The optimized solid dispersions were prepared by using 
the excipients as lactose were co-grinded in pestle and 
motor (except talc and magnesium stearate) and passed 
through mesh no. 60 and then added talc and magnesium 
stearate and mixed for 5 minutes and prepared hard 
gelatin capsules. 
Evaluation Parameters of Capsules
7
 
General appearance 
The general appearance of a capsule shell, its visual 
identification and over all ‘elegance’ is essential. 
Weight variation test 
The weight variation test was performed on weighing 
the intact the capsules individually and the average 
weight is determined. The tests requirements were met if 
none of the individual weighs are less than 90% or more 
than 110% of the average. If the original 20 did not meet 
these criteria, the individual net weighs are determined. 
These were averaged and differences were determined 
between individual net content and the average.  
Disintegration test 
In vitro disintegration time was determined using 
disintegration test apparatus. If the capsule floats on to 
the surface of the medium, a disc may be added. If the 
capsules adhere to the discs, attach a removable piece of 
stainless steel woven gauze with mesh apparatus of 
2.00mm to the upper plate of the basket rack assembly 
and carry out the test omitting the discs. In this case, 
each capsule was placed in each of six tubes of 
apparatus and a disc was added to each tube that is three 
inches long, open at the top, and held against a 10 mesh 
screen at the bottom end of the basket rack assembly. 
The basket rack assembly was positioned in a one litre 
of distilled water at 37
o
C ± 20
o
C. The time taken for the 
capsule to disintegrate completely and pass through the 
screen was measured. Operate the apparatus for 30min 
unless otherwise directed. 
Content uniformity 
The content uniformity was performed by specified 
individual monographs. The requirements are met for 
the capsules if 9 of the 10 are specified potency range of 
85 to 115% and tenth not outside 75 to 125%. 
In vitro dissolution test  
The dissolution studies were performed on the 
formulated capsule dosage forms in phosphate buffer pH 
6.8. by using rotating paddle method and equivalent to 
10mg of pure drug and capsule dosage form was added 
to 900 ml of phosphate buffer pH 6.8 (100rpm at 
37±0.5
o
C) and 10ml of aliquots were withdrawn at 
different time intervals and immediately filtered and 
replaced with 10ml of freshly prepared dissolution 
medium. The concentration of SIM was measured 
spectrophotometrically at 239.5nm and (%DE60) & % 
drug released of the capsules was determined and 
compared with the pure drug. 
Stability studies  
Accelerated stability studies were performed on 
prepared solid dispersion capsule dosage form in amber 
coloured screw capped bottles and were checked as per 
ICH guidelines at 40±2ºC and 75± 5% RH up to one 
month. The capsules were kept in stability chamber. 
Samples were removed at regular intervals as initial, 7 
days, 14 days, 21 days and 30 days and were analyzed 
for physical characterization, content uniformity and in 
vitro dissolution studies. The similarity factor (f2) was 
used as a basis to compare dissolution proﬁles. The 
dissolution proﬁles are considered to be similar when f2 
is between 50 and100 and calculated by the given 
formula: 
 
 Eq. 6 
Where, n is the dissolution time and Rj and Tj are the 
reference and test dissolution values at time t. (Morre 
Flamer equation). 
Physiochemical Characterisation of Pure Drug 
The sample of pure drug was characterised by its color, 
odor, taste and texture as given in officials (Indian 
pharmacopoeia). 
 
Similarly, It is white in color and 
crystalline nature and its melting point was 138.0
o
C 
determined by Capillary method which is similar with 
literature value. 
Maximum Absorption of Wavelength of Pure Drug 
The maximum absorption wavelength of pure drug was 
observed in distilled water as shown in the given fig 1. 
 
Figure 1: Scan graph of Simvastatin in Distilled water 
Preparation of Standard Plot in Distilled water 
The calibration plot of various concentrations of drug 
was found to be linear concentration range of 2.5 to 
15µg/ml at  239.0 nm in distilled water as shown in the 
Fig. 2.  
Kaur et al                                                                                                                Journal of Drug Delivery & Therapeutics. 2018; 8(2):73-82                     
ISSN: 2250-1177                                                                               [77]                                                                              CODEN (USA): JDDTAO 
 
Figure 2: Standard curve of Simvastatin in distilled 
water 
RESULTS AND DISCUSSION 
Characterisation parameters of LBG/MLBG 
The characterised parameters of gum was determined by 
its viscosity, angle of repose and density parameters and  
excessive heating was performed in hot air oven and 
reduces its value that forms modified locust bean gum as 
shown in the given Table no.2. 
Table 2: Characterisation parameters of LBG/MLBG 
Data are expressed as mean ± S.D. (n=3) 
Phase solubility studies 
The solubility profile of pure drug was determined by 
plotting the graph between the solubility of drug against 
concentration of polymer (%) in aqueous solution and 
type of solubility diagram, which shows the linear 
increase in the solubility of drug with increased 
concentration of carrier R
2
 value of 0.999 and giving an 
AL type solubility diagram (23). Solubility data of 
Simvastatin in different concentration of modified locust 
bean gum as shown in the shown in Fig 3. 
  
Figure 3: Effect of increasing concentration of 
MLBG on solubility of pure drug 
Characterisation of Solid dispersions  
Determination of percentage yield and drug content  
The drug content of the pure drug and solid dispersions 
was determined as 98.22-97.01%±0.01 and % Yield of 
prepared solid dispersions determined as increased from 
72.6-83.2±0.24% and decreased at higher concentration 
ratios cause difficult in sieving due to higher polymer-
surfactants ratios and deviate values of standard 
deviation in percent yield. 
Determination of solubility of solid dispersions 
Solubility data of pure drug and different solid 
dispersions as shown in given Table 3. 
Table 3: Solubility data of different solid dispersions 
with Poloxamer188 
Formulation codes Solubility(µg/ml) 
Poloxamer 188 (4 % w/w) 
SIM 22 9.52±0.00 
SIM 23 20.08±0.00 
SIM 24 43.67±0.63 
Poloxamer 188 (8 % w/w) 
SIM 25 12.55±0.00 
SIM 26 27.31±0.29 
SIM 27 48.78±0.24 
Poloxamer 188 (12 % w/w) 
SIM 28 18.58±0.00 
SIM 29 42.87±0.56 
SIM 30 53.48±0.46 
Data are expressed as mean ± S.D. (n=3) 
In-vitro drug release studies 
The In-vitro release of pure drug and different solid 
dispersions were determined as shown in Table 6. and 
plotted the graph between % drug released vs. time as 
shown below from Fig. 4 – 6 respectively. 
 
Figure 4: In-vitro dissolution profile of %pure drug 
released vs. time solid dispersions with Poloxamer 188(4%) 
 
Figure 5 In-vitro dissolution profile of %pure drug released 
vs. time solid dispersions with Poloxamer 188 (8%) 
 
Figure 6: In-vitro dissolution profile of %pure drug 
released vs. time solid dispersions with Poloxamer 
188(12%) 
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Time(mins) 
Pure drug SIM 28 
SIM 29 SIM 30 
Parameters LBG MLBG 
Viscosity(cps) 1661±2.1 581±2.6 
Angle of repose 38.836±0.45 37.736±0.19 
Carrs index (%) 21.6±.27 19.2±.57 
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Experimental Design  
The experimental designs were applied on the above prepared solid dispersions which is shown as below: 
Table 4: Composition of Factorial Design Batches with Poloxamer 188 
 
X1 drug to polymer ratio, X2 concentration of surfactants 
Poloxamer 188 %DE60 dissolution efficiency at 60 min. 
The regression analysis results (p value) of the variables 
on percentage dissolution efficiency at 60 min and 
percent of yield of solid dispersion are shown in Table 5. 
 
Table 5: Result of Regression Analysis 
 
 
 
 
 
 
The ANOVA results of solid dispersions are shown in 
Table 6. According to p value, full model or reduced 
model can be selected, so in the present study, full 
model having both significant and non significant p 
values was used in obtaining dependent variables 
because the fitness of full model to the system is better 
than reduced model. 
    
Table 6: The Results of Analysis of Variance 
 
The equation can be generated by putting values of 
coefficients in following equation in terms of coded 
factors. 
Dissolution efficiency 
Y= b0 + b1X1 + b2 X2+ b12 X1X2 + b11(X1)
2+ b22(X2)
2                         
Y = 64.59+ 15.35X1 + 4.23X2+ 1.29 X1X2 + 8.69(X1)
2+ 1.15 
(X2)
2    
% Yield 
Y= b0 + b1X1 + b2 X2+ b12 X1X2 + b11(X1)
2+ b22(X2)
2                        
 Y = 81.68+ 3.50X1 + 0.53 X2-0.95 X1X2 -4.67(X1)
2+0.13(X2)
2     
Coefficients with one factor indicate the effect of that 
particular factor, while the coefficients with more than 
one factor and those with second-order terms represent 
the interaction between those factors and the quadratic 
nature of the phenomena, respectively. Positive sign of 
the term indicates positive (additive) effect, while 
negative sign indicates negative (antagonistic) effect of 
Variables levels in coded 
Batch code X1  
(Ratio) 
X2 
(Concentration) 
%DE60±SD %Yield± SD 
SIM 22 -1 -1 57.81±0.143 72.5±0.24 
SIM 25 -1 0 59.58±0.723 73.5±0.10 
SIM 28 -1 +1 61.42±1.091 74.8±0.25 
SIM 23 0 -1 60.32±0.317 80.5±0.11 
SIM 26 0 0 65.17±0.063 81.9±0.22 
SIM 29 0 +1 73.3±0.143 82.9±0.03 
SIM 24 +1 -1 86.51±0.874 81.5±0.32 
SIM 27 +1 0 89.12±1.215 80.3±0.47 
SIM 30 +1 +1 95.30±0.913 80.0±0.39 
Coded values Actual values Concentration of surfactants 
Poloxamer 188 (% w/w) 
  
-1 1:2 4   
0 1:5 8   
+1 1:8 12   
Coefficients estimates 
Response b0 b1 b2 b12 b11 b22 R
2
 
%DE 60 65.49 15.35 4.23 1.29 8.69 1.15 0.9902 
p value - 0.0005 0.00217 0.3351 0.0136 0.5377 - 
% yield 81.68 3.50 0.53 -0.95 -4.67 0.13  
p value - 0.0012 0.1593 0.0732 0.0025 0.8054 - 
Response  df SS MS F R
2
 
%DE 60 Regression  
Error  
5 1682.22 336.44 60.87 0.9902 
 3 16.58 5.53 - - 
% yield Regression  
Error  
5 122.41 24.48 49.81 0.9881 
 3 1.47 0.49 - - 
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the factor on the response.  It can be concluded from the 
equations that X1 (drug: polymer ratio) shows the larger 
positive effect than term X2 (concentration of surfactant 
PXM 188) on percentage dissolution efficiency at 60min 
and yield percent. The quadratic terms of X1 and X2 also 
had effect on percentage dissolution efficiency at 60 min 
and yield percent. Fig.7 and 8 shows the contour plots 
and response surface plots for percentage dissolution 
efficiency. 
The reliability of the equations that describes the 
influence of factors on percentage dissolution efficiency 
at 60 min and % yield was assessed by preparing two 
additional check points solid dispersions (batch PXM 
188 1 and PXM 188 2) in triplicate using the amount of 
X1 and X2 -1and +1 level. The experimental values and 
predicted values of each response are shown in Table 7. 
Equation was used to calculate percentage relative error 
between predicted values and experimental values of 
each response. The percentage relative error obtained 
from checkpoint batches was in the range of 1.2to 0.23. 
Low values of the relative error show that for both 
factors, there is a reasonable agreement of predicted 
values and experimental values. This proves the validity 
of model and confirms the effects of drug: polymer ratio 
and the concentration of surfactant PXM 188 on 
percentage dissolution efficiency at 60 min and yield 
percent.  
% Relative error = [(Predicted value- experimental 
value) / predicted value]*100    Eq.6.1. 
 
Table 7: Validation of Model Obtained Using Experimental and Predicted results of checking updates 
        
       
Figure 7: Contour plots with Poloxamer 188 showing a) Percentage dissolution efficiency at 60 min b) 
percentage yield. 
      
Figure 8: Response surface with Poloxamer 188 plots showing a) percentage dissolution efficiency at 60min b) 
Percentage yield. 
 
The contour lines indicated that the higher the polymer 
and increasing the concentration of Poloxamer 188, the 
more significant in the dissolution enhancement. 
However, for yield percent, decrease at higher polymer 
ratio was observed, which may be attributed to difficulty 
of sieving when higher polymer ratio was used. 
Characterization of Optimized Solid Dispersions  
 Differential scanning calorimetry  
In the optimized preparation, due to higher polymer 
concentration ratio and uniform distribution of drug in 
the crust of polymer which indicates its miscibility of 
molten drug in polymer. Absence of sharp peak for the 
drug indicates that the drug is completely distributed 
homogenously in an amorphous nature state within the 
solid dispersions without any interaction as shown in the 
Fig. 9. 
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Batch code Variables %DE60 
Predicted 
%DE 60  
±SD  
Exp 
%Rel 
error 
%Yield  
Predicted 
%Yield  
± SD  
Exp. 
%Rel 
Error X 1 X 2 
PXM 1881 -1 +1 62.92 63.71±2.6 1.2 75.1 74.5±0.75 0.79 
PXM 188 2 +1 -1 85.16 84.17±0.51 1.1 81.06 82.9±0.88 0.23 
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Figure 9: DSC Thermogram of optimized formulation with Poloxamer 188 
Fourier transform infrared spectroscopy 
Infrared spectra of pure drug, Poloxamer 188 and 
optimized solid dispersion as shown in the given figures 
and exhibited significant decrease in intensity of O-H 
stretching vibrations which may be due to intermolecular 
hydrogen bonding in the optimized solid dispersions. 
The spectra peaks of drug were almost unchanged in the 
optimized solid dispersions which indicate that the 
overall symmetry of molecule was not affected. 
  
 
          
 
Figure 10: FTIR spectra of pure drug, Poloxamer 188 and optimised solid dispersion 
Powder x-ray diffraction analysis (XRD)  
The X-ray diffraction studies of Poloxamer 188 and 
optimized solid dispersions as shown in Fig. 11. 
Poloxamer 188 shows sharp peaks at 17
o
, 19
o, 
22
o 
when 
compared with that of simvastatin and shows with 
reduced peak height area were observed, this indicates 
the reduced in the crystallinity nature of the simvastatin 
as some of the drug converted into the amorphous form 
in the solid dispersions. 
 
 
Figure 11: X-ray diffraction of ploxamer188 and optimized formulation 
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Scanning electron microscopy (SEM) 
Simvastatin was highly crystalline material and 
characterised by its needle shaped crystals and the 
crystals of solid dispersions of drug did not show any 
needle shaped crystals and shows uniform dispersion of 
the drug in the polymeric matrix of the polymer and 
surfactant was observed in the solid dispersions and that 
reduces the crystallinality nature of the drug and changes 
into an amorphous form as shown in the given Fig.12.
 
     
Figure 12: Scanning electron photomicrograph of optimized solid dispersion Poloxamer 188 at 300 and 600X 
The optimized solid dispersions were filled into hard gelatin capsule shell and the final capsule dosage forms by using 
lactose, talc and other excipients were prepared and designated as C3. 
Evaluation Parameters of Capsules 
Table 8: Evaluation parameters of Capsule dosage form C3 with Poloxamer 188 
Formulation code C3 Weight variation 
(mg) 
Disintegration time 
(min) 
Content uniformity 
(%) 
1 238 ± 0.001 25 98.54 ± 0.27 
2 244 ± 0.005 26 96.93 ± 0.05 
3 241 ± 0.125 28 96.90 ± 0.055 
4 236 ± 0.126 31           97.03 ± 0.05 
5 239 ± 0.458 29 96.96 ± 0.05 
6 239 ± 0.235 31 97.58 ± 0.03 
7 236 ± 0.259 27 98.64 ± 0.03 
8 235 ± 0.369 30 97.71 ± 0.05 
9 233 ± 0.258 26 99.96 ± 0.05 
10 235 ± 0.240                28 98.22±0.06 
Data are expressed as mean ± S.D (n = 3) 
 
Figure 13: In vitro dissolution profile of %drug released vs time of pure drug and Capsule dosage forms 
CONCLUSION 
Result was observed from the experimental design that 
significantly influences the dependent variables %DE60 
and %yield. Optimized value was formulated into 
capsule dosage form and characterised by its different 
parameters as it shows the crystalline nature of the drug 
and convert into amorphous form and dissolution rate 
increases was found to be 99% by adding the surfactant 
also improves the solubility of poorly soluble drug.  The 
application of experimental study was used for the 
optimization for the formulation that helps in reaching 
the optimum point with corrected value in the shortest 
time.
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